RXST
RxSight, Inc.
Medical - Devices
Market Cap$239M
5Y Perf.-63.8%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
RXST vs LMAT vs ATRC vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
LMAT
LeMaitre Vascular, Inc.
Medical - Instruments & Supplies
Market Cap$2.46B
5Y Perf.+98.1%
ATRC
AtriCure, Inc.
Medical - Instruments & Supplies
Market Cap$1.41B
5Y Perf.-67.1%
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-89.1%
RXST vs LMAT vs ATRC vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RXST | LMAT | ATRC | NVCR |
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $239M | $2.46B | $1.41B | $1.92B |
| Revenue (TTM) | $127M | $256M | $552M | $674M |
| Net Income (TTM) | $-47M | $62M | $-5M | $-173M |
| Gross Margin | 77.0% | 72.4% | 75.5% | 75.2% |
| Operating Margin | -43.4% | 28.5% | -0.4% | -27.2% |
| Forward P/E | — | 37.2x | 370.7x | — |
| Total Debt | $11M | $186M | $88M | $290M |
| Cash & Equiv. | $20M | $28M | $167M | $103M |
RXST vs LMAT vs ATRC vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RXST
LMAT
ATRC
NVCR
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| RxSight, Inc. (RXST) | 100 | 36.3 | -63.8% |
| LeMaitre Vascular, … (LMAT) | 100 | 198.1 | +98.1% |
| AtriCure, Inc. (ATRC) | 100 | 32.9 | -67.1% |
| NovoCure Limited (NVCR) | 100 | 10.9 | -89.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RXST vs LMAT vs ATRC vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LMAT leads in 6 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. AtriCure, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
RXST
RxSight, Inc.
The Specific-Use Pick
RXST plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
LMAT
LeMaitre Vascular, Inc.
The Income Pick
LMAT carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 15 yrs, beta 0.57, yield 0.7%
- 6.1% 10Y total return vs ATRC's 95.1%
- Lower volatility, beta 0.57, Low D/E 47.2%, current ratio 12.89x
- Beta 0.57, yield 0.7%, current ratio 12.89x
Best for: income & stability and long-term compounding
ATRC
AtriCure, Inc.
The Growth Play
ATRC is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 14.9%, EPS growth 74.7%, 3Y rev CAGR 17.4%
- 14.9% revenue growth vs RXST's -3.9%
Best for: growth exposure
NVCR
NovoCure Limited
The Secondary Option
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATRC | 14.9% revenue growth vs RXST's -3.9% |
| Value | LMAT | Better valuation composite |
| Quality / Margins | LMAT | 24.3% margin vs RXST's -36.6% |
| Stability / Safety | LMAT | Beta 0.57 vs NVCR's 2.20, lower leverage |
| Dividends | LMAT | 0.7% yield; 15-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | LMAT | +33.3% vs RXST's -61.1% |
| Efficiency (ROA) | LMAT | 10.3% ROA vs NVCR's -16.5%, ROIC 9.7% vs -16.4% |
RXST vs LMAT vs ATRC vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
FY 2025
Segment breakdown not available.
RXST vs LMAT vs ATRC vs NVCR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLMATLAGGINGNVCR
Who Leads Where
LMAT leads in 4 of 6 categories
RXST leads 0 • ATRC leads 0 • NVCR leads 0 • 1 tied
Explore the data ↓NVCRNovoCure Limited
0leads
ATRCAtriCure, Inc.
0leads
RXSTRxSight, Inc.
0leads
LMATLeMaitre Vascular, In…
4leads
6 Total Categories
CATEGORYLEADERvs RXSTvs ATRCMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LMAT3/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
LMAT6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
LMAT6/6
Risk & VolatilityBeta, volatility, and downside exposure
LMAT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LMAT leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 5.3x RXST's $127M. LMAT is the more profitable business, keeping 24.3% of every revenue dollar as net income compared to RXST's -36.6%. On growth, ATRC holds the edge at +14.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RXSTRxSight, Inc. | LMATLeMaitre Vascular… | ATRCAtriCure, Inc. | NVCRNovoCure Limited |
|---|---|---|---|---|
| RevenueTrailing 12 months | $127M | $256M | $552M | $674M |
| EBITDAEarnings before interest/tax | -$57M | $81M | $13M | -$165M |
| Net IncomeAfter-tax profit | -$47M | $62M | -$5M | -$173M |
| Free Cash FlowCash after capex | -$2M | $79M | $54M | -$48M |
| Gross MarginGross profit ÷ Revenue | +77.0% | +72.4% | +75.5% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -43.4% | +28.5% | -0.4% | -27.2% |
| Net MarginNet income ÷ Revenue | -36.6% | +24.3% | -0.8% | -25.7% |
| FCF MarginFCF ÷ Revenue | -1.8% | +30.9% | +9.7% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -18.5% | +11.2% | +14.3% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -90.0% | +41.7% | +101.6% | -100.0% |
LMAT leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
Evenly matched — RXST and LMAT and ATRC each lead in 2 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, LMAT's 33.4x EV/EBITDA is more attractive than ATRC's 77.7x.
| Metric | RXSTRxSight, Inc. | LMATLeMaitre Vascular… | ATRCAtriCure, Inc. | NVCRNovoCure Limited |
|---|---|---|---|---|
| Market CapShares × price | $239M | $2.5B | $1.4B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $230M | $2.6B | $1.3B | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -6.11x | 42.82x | -115.83x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 37.17x | 370.67x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 2.21x | — | — |
| EV / EBITDAEnterprise value multiple | — | 33.39x | 77.75x | — |
| Price / SalesMarket cap ÷ Revenue | 1.78x | 9.85x | 2.63x | 2.92x |
| Price / BookPrice ÷ Book value/share | 0.87x | 6.29x | 2.70x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | 33.01x | 29.15x | — |
Evenly matched — RXST and LMAT and ATRC each lead in 2 of 6 comparable metrics.
Profitability & Efficiency
LMAT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
LMAT delivers a 16.2% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $-51 for NVCR. RXST carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), LMAT scores 7/9 vs RXST's 3/9, reflecting strong financial health.
| Metric | RXSTRxSight, Inc. | LMATLeMaitre Vascular… | ATRCAtriCure, Inc. | NVCRNovoCure Limited |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -17.0% | +16.2% | -1.0% | -50.8% |
| ROA (TTM)Return on assets | -15.1% | +10.3% | -0.7% | -16.5% |
| ROICReturn on invested capital | -13.3% | +9.7% | -0.6% | -16.4% |
| ROCEReturn on capital employed | -16.7% | +12.3% | -0.6% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.04x | 0.47x | 0.18x | 0.85x |
| Net DebtTotal debt minus cash | -$9M | $157M | -$79M | $187M |
| Cash & Equiv.Liquid assets | $20M | $28M | $167M | $103M |
| Total DebtShort + long-term debt | $11M | $186M | $88M | $290M |
| Interest CoverageEBIT ÷ Interest expense | -4852.10x | 24.99x | 0.47x | -96.80x |
LMAT leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
LMAT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LMAT five years ago would be worth $21,818 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, LMAT leads with a +33.3% total return vs RXST's -61.1%. The 3-year compound annual growth rate (CAGR) favors LMAT at 18.2% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | RXSTRxSight, Inc. | LMATLeMaitre Vascular… | ATRCAtriCure, Inc. | NVCRNovoCure Limited |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -44.1% | +34.9% | -29.2% | +28.3% |
| 1-Year ReturnPast 12 months | -61.1% | +33.3% | -8.3% | +1.1% |
| 3-Year ReturnCumulative with dividends | -70.1% | +65.2% | -41.8% | -75.7% |
| 5-Year ReturnCumulative with dividends | -63.7% | +118.2% | -64.2% | -91.3% |
| 10-Year ReturnCumulative with dividends | -63.7% | +608.6% | +95.1% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -33.1% | +18.2% | -16.5% | -37.6% |
LMAT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
LMAT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LMAT is the less volatile stock with a 0.57 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LMAT currently trades 91.4% from its 52-week high vs RXST's 34.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RXSTRxSight, Inc. | LMATLeMaitre Vascular… | ATRCAtriCure, Inc. | NVCRNovoCure Limited |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.73x | 0.57x | 1.03x | 2.20x |
| 52-Week HighHighest price in past year | $16.74 | $118.12 | $43.18 | $20.06 |
| 52-Week LowLowest price in past year | $5.30 | $78.35 | $26.62 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +34.6% | +91.4% | +64.4% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 43.5 | 48.3 | 45.0 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 741K | 244K | 669K | 1.5M |
LMAT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RXST as "Hold", LMAT as "Buy", ATRC as "Buy", NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -5.9% for LMAT (target: $102). LMAT is the only dividend payer here at 0.73% yield — a key consideration for income-focused portfolios.
| Metric | RXSTRxSight, Inc. | LMATLeMaitre Vascular… | ATRCAtriCure, Inc. | NVCRNovoCure Limited |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $10.75 | $101.50 | $50.67 | $33.50 |
| # AnalystsCovering analysts | 12 | 20 | 19 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | +0.7% | — | — |
| Dividend StreakConsecutive years of raises | — | 15 | — | — |
| Dividend / ShareAnnual DPS | — | $0.79 | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.8% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LMAT leads in 4 of 6 categories — strongest in Income & Cash Flow and Profitability & Efficiency. 1 category is tied.
Best OverallLeMaitre Vascular, Inc. (LMAT)Leads 4 of 6 categories
Loading custom metrics...
RXST vs LMAT vs ATRC vs NVCR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is RXST or LMAT or ATRC or NVCR a better buy right now?
For growth investors, AtriCure, Inc.
(ATRC) is the stronger pick with 14. 9% revenue growth year-over-year, versus -3. 9% for RxSight, Inc. (RXST). LeMaitre Vascular, Inc. (LMAT) offers the better valuation at 42. 8x trailing P/E (37. 2x forward), making it the more compelling value choice. Analysts rate LeMaitre Vascular, Inc. (LMAT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — RXST or LMAT or ATRC or NVCR?
On forward P/E, LeMaitre Vascular, Inc.
is actually cheaper at 37. 2x.
03Which is the better long-term investment — RXST or LMAT or ATRC or NVCR?
Over the past 5 years, LeMaitre Vascular, Inc.
(LMAT) delivered a total return of +118. 2%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LMAT returned +608. 6% versus RXST's -63. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — RXST or LMAT or ATRC or NVCR?
By beta (market sensitivity over 5 years), LeMaitre Vascular, Inc.
(LMAT) is the lower-risk stock at 0. 57β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 284% more volatile than LMAT relative to the S&P 500. On balance sheet safety, RxSight, Inc. (RXST) carries a lower debt/equity ratio of 4% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — RXST or LMAT or ATRC or NVCR?
By revenue growth (latest reported year), AtriCure, Inc.
(ATRC) is pulling ahead at 14. 9% versus -3. 9% for RxSight, Inc. (RXST). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to -33. 8% for RxSight, Inc.. Over a 3-year CAGR, RXST leads at 40. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — RXST or LMAT or ATRC or NVCR?
LeMaitre Vascular, Inc.
(LMAT) is the more profitable company, earning 23. 1% net margin versus -29. 0% for RxSight, Inc. — meaning it keeps 23. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LMAT leads at 27. 2% versus -35. 8% for RXST. At the gross margin level — before operating expenses — RXST leads at 76. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is RXST or LMAT or ATRC or NVCR more undervalued right now?
On forward earnings alone, LeMaitre Vascular, Inc.
(LMAT) trades at 37. 2x forward P/E versus 370. 7x for AtriCure, Inc. — 333. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — RXST or LMAT or ATRC or NVCR?
In this comparison, LMAT (0.
7% yield) pays a dividend. RXST, ATRC, NVCR do not pay a meaningful dividend and should not be held primarily for income.
09Is RXST or LMAT or ATRC or NVCR better for a retirement portfolio?
For long-horizon retirement investors, LeMaitre Vascular, Inc.
(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57), 0. 7% yield, +608. 6% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LMAT: +608. 6%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between RXST and LMAT and ATRC and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
LMAT pays a dividend while RXST, ATRC, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(RXST: -18.5% · LMAT: 11.2%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.